The Gladstone Office of Corporate Ventures and Translation facilitates interactions between our scientists and the biomedical industry, including venture capitalists, biotech firms, and large corporations. The Office’s primary goal is to translate the results of our basic science into therapeutics that help patients with cardiovascular, viral, or neurological diseases. Working in concert with Gladstone’s Intellectual Property Department, the Office of Corporate Ventures and Translation engages with companies interested in licensing our patented technology, collaborating on research goals, or launching startups. For example, this molecule-to-marketplace business unit facilitates technology transfer through collaborations with partners, such as Lundbeck, Bristol-Myers Squibb, and Takeda. If you’d like to explore opportunities to partner with Gladstone, please get in touch with Stephen Freedman, PhD, our vice president for Corporate Liaison & Ventures.